Frequently Asked Questions

A CRO selection consultant runs the sponsor side of choosing a contract research organization: defining real scope before the RFP goes out, building objective scoring criteria, pressure-testing proposals and bid-defense claims, and translating the winning proposal into a contract with enforceable governance. The output is a partnership structured for accountability.

Start with choosing the right CRO by scoping the trial's actual complexity, then match it against your own internal capability and governance maturity. Weight therapeutic and modality experience, named staff continuity, quality culture and financial stability above headline price. Verify what you are told through references and past performance data rather than the capabilities deck.

Beyond capabilities and pricing, an effective RFP asks how the CRO will behave under pressure: staff retention and turnover, named functional leads and their continuity, escalation paths and decision rights, governance cadence, performance metrics, and how database lock actually went on comparable studies.

CRO oversight is the sponsor's system for monitoring and directing delegated work: defined decision rights, a governance cadence tiered to risk, escalation thresholds, metrics tied to action, and documented evidence of decisions taken. Under ICH E6(R3) the sponsor maintains accountability for quality and safety regardless of what is outsourced.

Enough to see risk early and act on it, not more meetings for their own sake. Adding trackers, dashboards and approval layers creates administrative drag without creating control. Tier governance cadence to the study's actual risk profile, with defined escalation thresholds and leading indicators.

A dedicated sponsor-side capability for overseeing outsourced delivery. The CRO management function sets decision rights, assigns cross-functional ownership, defines escalation protocols and performance metrics, and maintains the tooling - RACIs, governance charters, risk trackers, scorecards - that turns an outsourced program into a managed one.

Hiring a CRO management consultant usually occurs at one of three points: before issuing an RFP, while the selection decision is still open; when a program is drifting and governance is not surfacing problems early enough; or ahead of an inspection, when oversight documentation needs to hold up to scrutiny. Earlier is consistently cheaper than later.

Full-service delegates an integrated scope to a single CRO, which suits sponsors with thin internal infrastructure but concentrates dependency. FSP contracts specific functions to providers, giving more control while requiring the sponsor to integrate across them. Hybrid blends both. The right choice follows governance maturity, not price.

It depends on how much oversight capacity you genuinely have, not on which model looks cheapest. Full-service asks less day-to-day integration but more governance discipline. FSP demands cross-functional coordination the sponsor must supply. The costliest mistake is picking a model that assumes internal capability you have not built.

Three recur. Hedged staffing language such as “anticipated” or “subject to availability.” Governance described as “robust” with no decision rights, escalation path or named owners. And assumptions that look aggressive - fast enrollment, thin monitoring - which tend to return later as change orders and deviations.

No. You can outsource execution, but accountability for trial quality and participant safety stays with the sponsor. ICH E6(R3) makes this explicit - a vendor's failure surfaces as a sponsor finding at inspection. That is why a CRO management function is needed even when nearly all delivery is outsourced.

Rarely because of bad science. More often a program quietly becomes someone's second priority. CROs read priority from response clarity and executive engagement rather than contract language, so when sponsor decisions slow and escalations go unowned, attention shifts toward programs that are being actively governed.

No. Contracts establish the commercial and legal foundation, but when timelines slip or enrollment stalls, what determines the outcome is governance - decision rights, metrics that trigger action, escalation pathways and documentation. Contracts are rarely what anyone reaches for when a study is under real pressure.

Tie every metric to a consequence. If a number does not produce a decision, an escalation or a behavior change, it is status reporting. Define escalation thresholds in advance, name an owner and a deadline for each action, and state what success looks like before the next review.

Governance that produces documentation without decisions. Standing meetings with no purpose, minutes with no owner or change of course, escalations nobody holds, metrics reviewed but never acted on. It satisfies an auditor's checklist while delivering none of the protection real oversight is supposed to provide.

ICH E6(R3) is the revised Good Clinical Practice guideline from the International Council for Harmonisation. It reframes GCP around risk-proportionate quality - critical-to-quality factors, risk-based monitoring, and explicit sponsor accountability for oversight of delegated activities - rather than uniform procedural compliance applied evenly everywhere.

It makes vendor quality systems a selection criterion rather than a procurement footnote. Because the sponsor retains ownership of trial quality and participant safety, a CRO's failure appears as a sponsor finding. Selection has to assess demonstrated quality culture, and contracts have to secure access to vendor system records.

Annex 2 addresses decentralized trial elements, real-world data and pragmatic trial designs. It was adopted and published by ICH on 3 June 2026. These approaches are increasingly standard, but they raise governance demands: remote visits and data originating outside the traditional site widen the oversight surface considerably.

Directing oversight effort where failure would genuinely threaten participant safety or data integrity, rather than monitoring everything at equal intensity. In practice: identify critical-to-quality factors, size monitoring to them, use central review where it works better, and adjust as the risk picture shifts during the study.

The attributes of a trial where a failure would meaningfully compromise participant safety or the reliability of the results. Identifying them early is what makes proportional monitoring possible - it tells a lean team where to concentrate limited oversight capacity and where a lighter touch is defensible.

Build the record as the study runs rather than reconstructing it afterward. Keep contemporaneous decision logs, KPI and KRI outputs with trend analysis, issue and escalation logs, and documented vendor selection rationale. Inspectors look for evidence of deliberate, ongoing oversight - not a file assembled at the end.

A fractional clinical operations executive is a senior clinical operations leader engaged part-time, typically on monthly retainer, who takes real accountability rather than advising from the outside. Scope usually covers organizational and governance design, executive decision support across delivery and vendor management, and representation at board or sponsor level.

A company needs fractional leadership commonly during growth that has outpaced structure, a leadership gap or transition, a restructuring, or an inspection. The need is for senior judgment and accountability at a volume that does not yet justify a full-time executive hire.

A consultant recommends; a fractional executive owns outcomes. The engagement carries decision authority, accountability for delivery, and a seat in the governance forums where decisions actually get made rather than a report handed over at the end.

Clinical operators need the leadership skills that surface under delivery pressure: holding results-accountability rather than activity-reporting, having difficult conversations, negotiating with vendors and internal stakeholders, thinking critically under uncertainty, and carrying executive presence across cross-functional, multi-regional teams.

Shift the unit of accountability from activity to results. Reporting what was done is not the same as owning what was achieved. That requires explicit ownership, the skill to raise problems early rather than at the milestone, and leaders willing to have the conversation when a commitment slips.

A bespoke consulting engagement is work scoped around a specific situation rather than a standard service - a rapid operational assessment, a governance build, a facilitated workshop, or short-term support through a restructuring, inspection or transition. It suits problems that are time-sensitive, operationally novel, or politically complex.

Two main ways ABRA structures engagements: defined-scope projects for a specific deliverable such as a CRO selection or a governance build, and monthly retainers for ongoing leadership or oversight support. Bespoke engagements are scoped around the situation when neither standard shape fits.

ABRA is a boutique clinical operations advisory firm working with biotech, emerging biopharma, CROs and site networks. Services cover CRO selection and management, fractional executive leadership, leadership development, and bespoke engagements. Every engagement is delivered personally by the Managing Principal.

Biotech and emerging biopharma sponsors, growth-stage CROs, and site networks - typically organizations that need senior clinical operations judgment without the overhead of a full-time executive team.

Angela Brady is the Founder and Managing Principal of ABRA Clinical Consulting, with more than 28 years in drug development and clinical research including senior leadership roles at global CROs. Her experience spans complex programs across multiple therapeutic indications.

ABRA Clinical Consulting, Inc. is based in Raleigh, North Carolina, and works with sponsors, CROs and site networks globally. Enquiries go to contact@abraclinical.com.